Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies;Les progrès dans le traitement des cancers de la thyroide à l'ère des thérapies ciblées moléculaires

Bulletin du Cancer

Volumn 96, Issue 1, 2009, Pages 95-101

  Malouf, G ^a   Baudin, E ^a   Soria, J C ^a   Schlumberger, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Angiogenesis inhibitors; Medullary thyroid cancers; Molecular biology; Targeted therapies; Thyroid cancers; Tyrosine kinases inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; IODINE 131; MOTESANIB; PACLITAXEL; PLACEBO; SORAFENIB; VANDETANIB; PROTEIN KINASE INHIBITOR; RADIOACTIVE IODINE;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID MEDULLARY CARCINOMA; ADENOCARCINOMA; DRUG RESISTANCE; GENETICS; THYROID TUMOR; VASCULARIZATION;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ANGIOGENESIS INHIBITORS; DRUG RESISTANCE, NEOPLASM; HUMANS; IODINE RADIOISOTOPES; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS;

EID: 61549090221     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0798     Document Type: Review

References (52)

1. Colonna M, Grosclaude P, Remontet L, Schvartz C, Mace-Lesech J, Velten M, et al. Incidence of thyroid cancer in adults recorded by French cancer registries (1978-1997). Eur J Cancer 2002 ; 38(13) : 1762-8.
2. Are C, Shaha AR. Anaplastic thyroid carcinoma : biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006 ; 13(4) : 453-64.
3. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 ; 1 6(2) : 109-42.
4. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Par- mentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer : experience at the Gustave-Roussy Institute. Tumori 1990 ; 76(5) : 480-3.
5. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2008 ; 4(1) : 22-32.
6. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006 ; 6(4) : 292-306.
7. Lacroix L, Soria JC, Bidart JM, Schlumberger M. Oncogenes and thyroid tumors. Bull Cancer 2005 ; 92(1) : 37-43.
8. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 2001 ; 8(6) : 345-54.
9. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002 ; 13(1) : 3-16.
10. Kimura ET, Nikiforova MN, Zhu Z, Knaut JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer : genetic evidence for constitutive activation of the RET/PTC-RASBRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003 ; 63(7) : 1454-7.
11. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007 ; 148(3) : 936-41.
12. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPAR-gamma rearrangement in thyroid tumors : RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002 ; 26(8) : 1016-23.
13. Nikiforova MN, Lynch RA, Biddinger PW, Alexander, EK, Dorn 2nd GW, Tallini G, et al. Ras point mutations and PAX8- PPAR-gamma rearrangement in thyroid tumors : evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003 ; 88(5) : 2318-26.
14. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms : down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am j Pathol 2001 ; 158(3) : 987-96.
15. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993 ; 91(1) : 1 79-84.
16. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996 ; 276 (19) : 1575-9.
17. Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996 ; 81 (10) : 3740-5.
18. Messina M, Robinson BG. Technology insight : gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2007 ; 3(3) : 290-301.
19. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling Ml, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983 ; 309(16) : 937-41.
20. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998 ; 338(5) : 297-306.
21. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy, J Clin Endocrinol Metab 2006 ; 91(8) : 2892-9.
22. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999 ; 16(1) : 34-41.
23. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cis- platin in patients with advanced thyroid carcinoma. Cancer 1985 ; 56(9) : 2155-60.
24. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel : phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) group. Thyroid 2000 ; 10(7) : 587-94.
25. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer : a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986 ; 70(3) : 405-7.
26. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007 ; 8(2) : 148-56.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100(1) : 57-70.
28. Sivakumar B, Harry LE, Paleolog EM. Modulating angiogenesis : more versus less. JAMA 2004 ; 292(8) : 972-7.
29. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000 ; 10(4) : 349-57.
30. Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 2002 ; 12(11) : 953-61.
31. Cohen E, Vokes E, Rosen L, et al. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I Vol 25, No. 18S (June 20 Supplement), 2007 : 6008.
32. Gupta V, Puttaswamy K, Lassoued W, et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid cancer [abstract]. J Clin Oncol 25(18S) : 6017.
33. Kloos R, Ringel M, Knopp M, et al. Significant clinical and biologic activity of RafA/EGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC) : updated results of a phase II study. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006 : 5534.
34. Sherman S, Schlumberger M, Droz J, et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007 : 601 7.
35. Wells S, Gosnell J, Gagel R, et al. Vandetanib in metastatic hereditary medullary thyroid cancer : follow-up results of an open-label phase II trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1. Vol 25, No. 18S (June 20 Supplement), 2007 : 6018.
36. Kober F, Hermann M, Handler A, et al. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007 : 14065.
37. Schlumberger M, Elisei R, Sherman S, et al. Initial results from a phase 2 trial of motesanib diphosphate (AMG 706) in patients (pts) with medullary thyroid cancer (MTC). Annual Meeting of The Endocrine Society, Toronto, June 2007.
38. Pennell N, Daniels G, Haddad R, et al. A phase II study of gefi- tinib in patients with advanced thyroid cancer. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007 : 6020 Merci de compléter les auteurs à six avant et al.
39. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007 ; 92(9) : 3466-9.
40. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007 ; 157(2) : 215-20.
41. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005 ; 65(10) : 4238-45.
42. (-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001 ; 86(7) : 3430-5.
43. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 2005 ; 146(9) : 3967-74.
44. Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 2006 ; 12(18) : 5570-7.
45. Zhang Y, Jia S, Liu Y, Li B, Wang Z, Lu H, Zhu C. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun 2007 ; 28(4) : 251-5.
46. Chan P, Yau T, Epstein R, et al. Treatment outcomes in anaplastic thyroid carcinoma from 1966-2006 : failure of overall survival enhancement despite four decades of progress in surgery, radiotherapy and chemoradiation. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007 : 16537.
47. De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004 ; 60(4) : 1137-43.
48. Cooney M, Savvides P, Agarwala S, et al. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC).JClin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006 : 5580.
49. Ekman ET, Lundell G, Tennvall J, Wallin G. Chemotherapy and multimodality treatment in thyroid carcinoma. Otolaryngol Clin North Am 1990 ; 23(3) : 523-7.
50. Rougier P, Calmettes C, Laplanche A, Travagli JP, Lefevre M, Parmentier C, et al. The values of calcitonin and carcinoembryonic antigen in the treatment and management of nonfamilial medullary thyroid carcinoma. Cancer 1983 ; 51(5) : 855-62.
51. Saad MF, Fritsche Jr. HA, Samaan NA. Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1984 ; 58(5) : 889-94.
52. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006 ; 439(7074) : 358-62.